Solubilizate with curcumin and at least one cannabinoid as a further active substance

Abstract

In order to make available the health-promoting and healing properties of curcumin and/or cannabinoids to the human organism, the invention provides a solubilizate consisting of or comprising curcumin in a content equal to or less than 10 wt. %, and at least one cannabinoid as at least one further active substance, as well as at least one emulsifier with an HLB value in a range below 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids, and a solubilizate comprising, in particular consisting of at least one cannabinoid in a content of less than or equal to 10 wt. % and at least one emulsifier having an HLB value in a range of less than 18, preferably between 13 and 18, in particular polysorbate 80 or polysorbate 20 or at least one sucrose ester of edible fatty acids.

1 .- 30 . (canceled) 
     
     
         31 . A solubilizate, consisting of:
 a cannabinoid in an active amount of less than or equal to 10 wt. %,   an emulsifier comprising polysorbate 80, or a mixture of polysorbate 80 and polysorbate 20, or a mixture of polysorbate 80 and a sucrose ester of edible fatty acids,   between 0 and 10 wt. % curcumin,   between 0 and 20 wt. % ethanol,   between 0 and 10 wt. % water,   0 wt. % or more secondary phytochemicals,   0 wt. % or more natural phenols,   0 wt. % or more plant extracts, and   0 wt. % or more enzymes.   
     
     
         32 . The solubilizate as in  claim 31 ,
 wherein the curcumin is present in an active amount between 1 and 10 wt. %.   
     
     
         33 . The solubilizate as in  claim 31 ,
 wherein one or more of the secondary phytochemicals, the natural phenols, the plant extracts, and the enzymes is present in an amount greater than 0 wt. %.   
     
     
         34 . The solubilizate as in  claim 31 ,
 wherein the active amount of the cannabinoid is between 0.3 wt. % and 3 wt. %.   
     
     
         35 . The solubilizate as in  claim 31 ,
 wherein an amount of the emulsifier is at least 70 wt. %.   
     
     
         36 . The solubilizate as in  claim 31 ,
 wherein a diameter distribution of micelles in a dilution of the solubilizate with distilled water in a ratio of 1:500 under physiological conditions (pH 1.1 and 37° C.) extends from d10=6 nm to d90=20 nm.   
     
     
         37 . The solubilizate as in  claim 31 ,
 wherein a turbidity of the solubilizate is less than 25 FNU, measured by scattered light measurement using infrared light according to the specifications of the ISO 7027 standard at a dilution of the solubilizate in a ratio of 1:50 or 1:500 in water under physiological conditions (pH 1.1 and 37° C.).   
     
     
         38 . A capsule filled with the solubilizate as in  claim 31 ,
 wherein the capsule is in the form of a soft gelatin capsule or a hard gelatin capsule or a soft gelatin-free capsule or a hard gelatin-free capsule.   
     
     
         39 . A fluid containing the solubilizate as in  claim 31 ,
 wherein the fluid is selected from the group consisting of foods, dietary supplements, beverages, cosmetics, and pharmaceutical products.   
     
     
         40 . The fluid as in  claim 39 ,
 wherein the fluid comprises an aqueous dilution of the solubilizate.   
     
     
         41 . A method for treating and/or preventing diseases involving one or more of inflammation, cancer, Alzheimer's, Parkinson's, obesity, high cholesterol, elevated blood sugar, diabetes, metabolic syndrome, and/or autoimmune diseases, multiple sclerosis (MS), for reducing visceral fat, for thermogenesis, for lowering cholesterol, and/or glucose in the blood and/or triglycerides in the blood, for improving macular pigment density, for reducing oxidative stress and/or for reducing an accumulation of fat in the hepatocytes, for treating and/or preventing fatty liver disease, Friedreich's ataxia, lysosomal diseases, Tay-Sachs disease, arteriosclerosis, heart diseases, arthritis, comprising:
 administering the solubilizate as in  claim 31  to a dietary supplement consumer or a patient.   
     
     
         42 . A method for treating and/or preventing diseases, comprising:
 administering the solubilizate as in  claim 32  to a dietary supplement consumer or a patient in a dose of curcumin in the range from 0.5 mg/kg body weight to 1 mg/kg body weight.   
     
     
         43 . A method for treating and/or preventing diseases, comprising:
 administering the solubilizate as in  claim 33  to a dietary supplement consumer or a patient,   wherein the one or more substances comprises  Boswellia , and   wherein the solubilizate is administered to the dietary supplement consumer or patient in a  Boswellia  dose in the range from 1 mg/kg body weight to 2 mg/kg body weight.   
     
     
         44 . A method for treating and/or preventing diseases, comprising:
 administering the solubilizate as in  claim 33  to a dietary supplement consumer or a patient,   wherein the one or more substances comprises xanthohumol, and   wherein the solubilizate is administered to the dietary supplement consumer or patient in a xanthohumol dose in the range from 0.5 mg/kg body weight to 1 mg/kg body weight.   
     
     
         45 . A method for producing the solubilizate according to  claim 32 , comprising:
 (a) providing polysorbate 80, or a mixture of polysorbate 80 and polysorbate 20 or of polysorbate 80 and at least one sucrose ester of edible fatty acids;   (b) adding the at least one cannabinoid; and   (c) adding curcumin powder;   wherein   in step (a) a heating to a temperature in a range from 40° C. to 62° C., is carried out;   and wherein in step (b) a heating to a temperature in a range from 82° C. to 97° C., is carried out;   wherein step c) comprises maintaining this temperature;   wherein, optionally, before step (b) a step   (b1) adding water at a temperature in a range from 40° C. to 62° C. is carried out,   and/or wherein, optionally, in step   (b1) also adding ethanol at a temperature in a range from 40° C. to 62° C. is carried out.   
     
     
         46 . The method of  claim 45 ,
 wherein step (b) further comprises adding  Boswellia serrata  extract and/or xanthohumol.   
     
     
         47 . The method of  claim 45 ,
 wherein step (c) further comprises adding serrapeptase.   
     
     
         48 . A method, comprising:
 mixing a solubilizate which comprises a cannabinoid and no curcumin with the solubilizate as in  claim 32 .   
     
     
         49 . A method for producing the cannabinoid solubilizate according to  claim 31 , comprising:
 (a) providing polysorbate 80, or a mixture of polysorbate 80 and polysorbate 20 or of polysorbate 80 and at least one sucrose ester of edible fatty acids;   (b) adding the at least one cannabinoid;   wherein in step (a) a heating to a temperature at least in a range from 40° C. to 62° C., is carried out;   and wherein in step (b) a heating to a temperature in a range from 82° C. to 97° C., is carried out.   
     
     
         50 . The method of  claim 49 ,
 wherein in step (a) the temperature is increased to a value in the range from 82° C. to 97° C.   
     
     
         51 . The method of  claim 49 ,
 wherein before step (a) a step   (a1) mixing glycerol and the cannabinoid to produce a solution is carried out, and   wherein in step (a1) a heating to a temperature in a range from 82° C. to 97° C., is carried out.   
     
     
         52 . The method as claimed in  claim 49 ,
 wherein before step (a) a step   (a11) mixing of water and at least one sucrose ester of an edible fatty acid   is carried out, wherein in step (a11) a heating to a temperature at least in a range from 40° C. to 62° C., is carried out;   and a step   (a12) addition of polysorbate 20 and/or polysorbate 80 to the mixture produced in step (a11) is carried out, wherein in step (a12) a heating to a temperature in a range from 82° C. to 97° C., is carried out.